Can Cobenfy Cause Blurred Vision?
Yes, Cobenfy (xanomeline and trospium) can cause blurred vision as a documented adverse effect, occurring in 3% of patients in clinical trials compared to 0% with placebo. 1
Mechanism and Clinical Significance
Cobenfy contains trospium chloride, an antimuscarinic agent that blocks peripheral muscarinic receptors. While trospium is included specifically to mitigate peripheral cholinergic side effects of xanomeline, blurred vision is a known anticholinergic effect that occurs when muscarinic receptors in the eye are blocked 2, 3. This is distinct from the intermittent nearsightedness (myopia) that can occur with other antimuscarinic medications like atropine used for myopia control 4.
Incidence and Characteristics
In pooled 5-week placebo-controlled trials of 504 patients with schizophrenia:
- Blurred vision occurred in 3% of Cobenfy-treated patients versus 0% with placebo 1
- The effect was generally mild to moderate in intensity and transient 5
- Vision-related adverse events were part of the broader anticholinergic side effect profile
Important Clinical Considerations
Contraindication for narrow-angle glaucoma: Cobenfy is contraindicated in patients with untreated narrow-angle glaucoma, as antimuscarinic effects can precipitate acute angle-closure glaucoma 1. Patients should be monitored for:
- Red eyes
- Blurred vision
- Seeing halos or bright colors around lights
- Eye pain or discomfort
- Severe headache
This is NOT the same as intermittent nearsightedness (accommodative spasm) that occurs with high-dose atropine used for myopia control in children. That phenomenon involves temporary changes in refractive error due to ciliary muscle effects 4. Cobenfy's blurred vision is more consistent with typical antimuscarinic ocular effects: reduced accommodation, pupillary dilation, and potential precipitation of angle-closure in susceptible individuals.
Management Approach
- Screen patients for narrow-angle glaucoma risk before initiating treatment - those with anatomically narrow angles should receive ophthalmologic clearance 3
- Counsel patients that blurred vision may occur but is typically mild and transient
- If blurred vision develops and is bothersome, consider dose reduction as the effect is dose-related
- Discontinue immediately if signs of acute angle-closure glaucoma develop (severe eye pain, vision changes, halos around lights) 1
The overall discontinuation rate due to adverse events was similar between Cobenfy (6%) and placebo (4%), with blurred vision not being a major driver of discontinuation 1. This suggests that while blurred vision occurs, it is generally tolerable for most patients.